3 Versus 6 Cycles of CMF in Breast Cancer Patients with 1 to 9 Positive Nodes: Results of the German Adjuvant Breast Cancer Group (GABG) III Trial
Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial
Does pretreatment PSA add to predicting long-term survival from prostate cancer?
Induction Chemotherapy for High Grade Extremity Soft Tissue Sarcomas: Histologic Response and Correlation of Tumor Necrosis to Long Term Disease Free and Overall Patient Survival
Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results (Abstract 1502)
The Role of Radiotherpay and Tamoxifen in the Management of Node Negative Invasive Breast Cancer </= 1.0 cm Treated with Lumpectomy: Preliminary Results of NSABP Protocol B-21
English
News
Death Rate for All Cancers Down in U.S. From 2000 to 2009

Jan 8, 2013 - From 2000 to 2009, there was a general decrease in the death rates for all cancers combined for men and women, although the incidence of some cancers continued to rise, according to a report published online Jan. 7 in the Journal of the National Cancer Institute.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información